Updated results of a prospective noninterventional study of everolimus after failure of the first VEGF-targeted therapy.
Michael Staehler(München Klinik), Christian Doehn(University of Lübeck), Thomas Koepke(University Hospital Münster), Manfred Kindler(Praxis), Susanne Kloss, Thomas Steiner(Helios Klinikum Erfurt), Friedrich Overkamp, Andreas Jakob(Offenburg University of Applied Sciences), Lothar Bergmann(Universität Ulm), Joerg Schmitz(Springer Nature (Germany)), Ulrich Kube(Goethe Institut), Peter J. Goebell(Friedrich-Alexander-Universität Erlangen-Nürnberg), Gernot Guderian(University of Basel), Gabriel Steiner, Steffen Weikert(St. Hedwig-Krankenhaus), Jan Janßen
Cited by 0
Related Papers
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|594
High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term Outcome
|Blood|1997|352
Plk4 <i>trans</i>-autophosphorylation regulates centriole number by controlling βTrCP-mediated degradation
|Journal of Cell Science|2010|220